Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  AMAG Pharmaceuticals, Inc.    AMAG

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/14/2017 08/15/2017 08/16/2017 08/17/2017 08/18/2017 Date
17.35(c) 16.6(c) 17.45(c) 16.95(c) 17.15 Last
571 922 547 800 836 021 868 168 665 301 Volume
+1.46% -4.32% +5.12% -2.87% +1.18% Change
More quotes
Financials ($)
Sales 2017 650 M
EBIT 2017 52,0 M
Net income 2017 10,2 M
Debt 2017 560 M
Yield 2017 -
Sales 2018 542 M
EBIT 2018 22,3 M
Net income 2018 -27,7 M
Debt 2018 610 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 1,78x
EV / Sales2018 2,23x
Capitalization 598 M
More Financials
Company
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia.It focuses on the development and commercialization of Feraheme injection for intravenous or IV, use to treat iron... 
Sector
Pharmaceuticals
Calendar
11/02Earnings Release
More about the company
Surperformance© ratings of AMAG Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on AMAG PHARMACEUTICALS, INC.
08/08 AMAG Pharmaceuticals Appoints Oscar Sanchez as Vice President of Quality
08/04 AMAG PHARMACEUTICALS : Pharmaceuticals, Inc. - AMAG Completes Feraheme FDA Submi..
08/03 AMAG PHARMACEUTICALS, INC. (NASDAQ : AMAG) reported earnings of ($0.40) per shar..
08/03 AMAG PHARMACEUTICALS : reports 2Q loss
08/03 AMAG PHARMACEUTICALS,INC. (NASDAQ : AMAG) Files An 8-K Results of Operations and..
08/03 AMAG PHARMACEUTICALS INC. : Results of Operations and Financial Condition, Finan..
08/03 AMAG Pharmaceuticals Announces Second Quarter 2017 Financial Results and Prov..
08/03 AMAG Completes Feraheme® (ferumoxytol) FDA Submission for the Treatment of Al..
08/03 AMAG PHARMACEUTICALS, INC. : Investor Network: AMAG Pharmaceuticals, Inc. to Hos..
07/24 AMAG Pharmaceuticals Launches Intrarosa™ (prasterone) in the U.S. &ndas..
More news
Sector news : Pharmaceuticals - NEC
01:15pDJMERCK AND : Scientists, Out $12 Million, Sue Delaware Over Seizure of Their Stoc..
08:35aDJASTRAZENECA : FDA Approves AstraZeneca's Ovarian Cancer Treatment Lynparza Table..
08/17 FDA expands use of AstraZeneca/Merck ovarian cancer drug
08/17 Drugmaker Hikma trims sales forecasts, shares fall
08/17 Exclusive - Taking aim at China, India tightens power grid, telecoms rules
More sector news : Pharmaceuticals - NEC
Latest Tweets
07:16pLouisiana State Employees Retirement System Has $263,000 Position in AMAG Pha.. 
07:12pLouisiana State Employees Retirement System Has $263,000 Position in AMAG Pha.. 
08/10AMAG Pharmaceuticals's hold rating reiterated at Cowen and Company.  
08/08AMAG Pharmaceuticals Appoints Oscar Sanchez as Vice President of Quality  
08/08$AMAG AMAG Pharmaceuticals Appoints Oscar Sanchez as Vice President of Qualit.. 
More tweets
Qtime:19
News from SeekingAlpha
08/06 3 THINGS IN BIOTECH YOU SHOULD LEARN : August 6, 2017
08/03 AMAG Pharmaceuticals, Inc. 2017 Q2 - Results - Earnings Call Slides
08/03 AMAG Pharmaceuticals' (AMAG) CEO Bill Heiden on Q2 2017 Results - Earnings Ca..
08/03 AMAG Pharmaceuticals EPS of -$0.40
08/02 Notable earnings before Thursday?s open
Chart AMAG PHARMACEUTICALS, INC.
Duration : Period :
AMAG Pharmaceuticals, Inc. Technical Analysis Chart | AMAG | US00163U1060 | 4-Traders
Technical analysis trends AMAG PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 9
Average target price 22,9 $
Spread / Average Target 35%
EPS Revisions
Managers
NameTitle
William K. Heiden President, Chief Executive Officer & Director
Gino Santini Chairman
Edward H. Myles Chief Financial Officer, Treasurer & Senior VP
Julie Krop Chief Medical Officer & SVP-Regulatory Affairs
Nathan McBride Chief Information Officer & Senior VP-Innovation
Sector and Competitors
1st jan.Capitalization (M$)
AMAG PHARMACEUTICALS, INC.-51.29%598
JOHNSON & JOHNSON15.48%357 079
ROCHE HOLDING LTD.5.37%218 752
NOVARTIS10.59%218 545
PFIZER1.45%196 221
MERCK AND COMPANY5.05%168 660